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Serum Elastin-Derived Peptides and Anti-Elastin Antibody  
in Patients with Systemic Sclerosis
The elastin metabolism in systemic sclerosis (SSc) has been known to be abnormal. The 
authors investigated relationship between the clinical manifestations of systemic sclerosis 
(SSc) and serum levels of soluble elastin-derived peptide (S-EDP) and anti-elastin antibodies. 
Serum samples were obtained from 79 patients with SSc and 79 age- and sex-matched 
healthy controls. Concentrations of serum S-EDP and anti-elastin antibodies were 
measured by ELISA. The serum concentrations of S-EDP in SSc patients were significantly 
higher than in healthy controls (median, 144.44 ng/mL vs 79.59 ng/mL, P < 0.001). 
Serum EDP concentrations were found to be correlated with disease duration in SSc 
(P = 0.002) and particularly in diffuse cutaneous SSc (P = 0.005). Levels of anti-elastin 
antibodies were found to be more elevated in SSc patients than in healthy controls 
(median, 0.222 U vs 0.191 U, P = 0.049), more increased in diffuse cutaneous SSc than 
limited cutaneous SSc (median, 0.368 U vs 0.204 U, P = 0.031). In addition, levels of anti-
elastin antibodies were also found to be negatively associated with presence of anti-
centromere antibody (P = 0.023). The S-EDP levels were not found to be correlated with 
levels of anti-elastin antibodies. The increased S-EDP and anti-elastin antibody levels and 
association with clinical and laboratory characteristics may reflect the abnormal 
metabolism in SSc.
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INTRODUCTION
Systemic sclerosis (SSc) is a chronic multisystem autoimmune 
disease with a complex, multifactorial pathogenesis. Several in-
vestigators have shown that changes in matrix biology play an 
important role in the pathogenesis of SSc, which is character-
ized by an accumulation of collagen in the extracellular matrix 
by activated fibroblasts (1).
  Elastin is an extremely insoluble fibrous protein and a constit-
uent of the extracellular matrix (ECM). It is the main protein of 
elastic fiber and contributes to the elastic properties of several 
tissues, such as, the vascular wall, lungs, and skin (2). Further-
more, degradation of elastin by activated proteinases results in 
the pathologic release of large amounts of soluble elastin-de-
rived peptides (S-EDPs) (3, 4), and elevations of serum S-EDP 
have been reported in various diseases, such as emphysema, 
abdominal aortic aneurysm and atherosclerosis (5-7).
  In SSc, elastin production is increased in skin (8, 9), and the 
levels of elastin cross-linking product are increased in urine (10). 
In addition, previous reports have shown that levels of anti-elas-
tin antibody are elevated in SSc (11, 12). Therefore, we postulat-
ed that elastin degradation and S-EDP release into the circula-
tion would be elevated in SSc, and that abnormal elastin metab-
olism may provoke the production of anti-elastin antibody. In 
the present study, we analyzed serum levels of S-EDP and of anti-
elastin antibody in patients with SSc and searched for associa-
tions between these and the clinical manifestations of SSc. 
MATERIALS AND METHODS
Patients
Serum samples were drawn from SSc patients and controls after 
obtaining informed consent in Seoul National University Hos-
pital from 1998 to 2008. Seventy-nine SSc patients and 79 age- 
and sex-matched healthy controls were selected. Clinical mani-
festations were collected by reviewing medical records. The fol-Hong YJ, et al.  •  S-EDP and Anti-Elastin Antibody in Systemic Sclerosis
http://jkms.org   485 http://dx.doi.org/10.3346/jkms.2012.27.5.484
lowing clinical information was collected: age at enrollment and 
at disease onset, gender, cutaneous subset, autoantibody status 
(anti-centromere antibody and anti-Scl-70 antibody), modified 
Rodnan skin score, and major organ involvement, including the 
kidneys, heart, lungs, and pulmonary artery. Cutaneous subsets 
were classified as diffuse or limited based on the classification 
by LeRoy et al. (13) with some modification; the limited cutane-
ous subset was defined as those with scleroderma limited to the 
hands, face, feet and forearms. Major organ involvements were 
classified as follows. Interstitial lung disease was defined as the 
presence of bibasilar pulmonary fibrosis by chest radiography 
or high-resolution computed tomography without any evidence 
of other lung disease. Heart involvement was defined as the pres-
ence of major conduction disturbance, ventricular arrhythmia, 
heart failure, or persistent pericardial effusion for  ≥ 2 months. 
Pulmonary hypertension was defined as a systolic pulmonary 
artery pressure of  > 35 mmHg by echocardiography. The num-
ber of patients with renal involvement was only 1, and thus, renal 
involvement was excluded from the analysis. Disease duration 
was calculated from the appearance of the first symptoms be-
sides Raynaud’ phenomenon. 
 
Competitive enzyme-linked immunosorbent assay 
(ELISA) of S-EDP
S-EDP concentration was determined by competitive ELISA 
adapted from a protocol described by Sivaprasad et al. (14). Sol-
uble α-elastin was obtained from human aorta (Sigma-Aldrich, 
Poole, UK), and the rabbit anti-human elastin IgG (Elastin Prod-
ucts Co., Owensville, MO, USA) was raised against α-elastin pre-
pared from human aorta.
  Briefly, the wells of a microtiter plate (Nunc, Fischer Scientific, 
Loughborough, UK) were coated with 150 μL α-elastin (1 μg/mL) 
in 0.1 M sodium carbonate (pH 9) by incubating at room tem-
perature for 2 hr. The plate was then washed three times with 
phosphate-buffered saline (PBS) containing 0.05% (v/v) Tween 
20 (PBST). A curve was generated using dilutions of human aor-
tic α-elastin (0-1 μg/mL). Anti-α-elastin antibodies (1:3,000) in 
PBST and 3% (w/v) bovine serum albumin (PBST-3% BSA) were 
preincubated with variable dilutions of α-elastin in PBST-3% BSA 
for 1 hr 30 min at 37°C. These solutions were then transferred to 
the coated plate and incubated at 37°C for 1 hr. The preincuba-
tion period before adding the solution to α-elastin-coated mi-
crotiter plate creates the competitive aspect of the ELISA. Before 
adding detection antibody to wells, the microtiter plate wells 
were washed with PBST three times. Then, horse radish peroxi-
dase (HRP) conjugated goat anti-rabbit IgG antibody (Santa 
Cruz Biotechnology/Autogen Bioclear, Santa Cruz, CA, USA) was 
added to each well. The plate was incubated for 20 min at room 
temperature and again washed with PBST three times. Thereaf-
ter, 2,2´- azino-bis-3-ethylbenzthiazoline-6-sulfonic acid (ABTS) 
(Calbiochem, Darmstadt, Germany) buffer was added to each 
well, and the plate was incubated for up to 30 min at room tem-
perature. Absorbance was read at 405 nm using an automated 
plate reader (Molecular Devices, Sunnyvale, CA, USA). A stan-
dard curve was generated from absorbance readings obtained 
from α-elastin dilutions. Standards were analyzed in triplicate, 
and serum samples were analyzed in duplicate. S-EDP concen-
trations were calculated from the standard curve and are ex-
pressed as nanograms per milliliter.
ELISA for anti-elastin antibody
Anti-human elastin antibody assays were performed using a 
modified ELISA protocol (15). Briefly, human skin elastin pep-
tides were purchased from Elastin Products Co. (Owensville, 
MO, USA) in lyophilized form and dissolved in water to a final 
concentration of 25 μg/mL, and 40 μL aliquots of this working 
solution were used to coat high protein binding flat bottomed 
polystyrene microtiter plates (Immulon 4HBX, Fisher Scientific 
Company, Pittsburgh, PA, USA). The plates were then incubated 
at 37°C for 2 hr or alternatively at 4°C overnight. After washing 
with PBST, plates were blocked by adding 0.2% I-block (Tropix, 
Bedford, MA, USA) and incubated at 37°C for 2 hr. After wash-
ing, human serum samples were diluted in 100 mM sodium  
bicarbonate buffer (pH 9.4) in polypropylene microtiter plates 
and incubated at 37°C for 2 hr. After washing, biotinylated chicken 
anti-human IgG antibody was added and plates were incubated 
at 37°C for 2 hr. Plates were washed, alkaline phosphatase con-
jugated streptavidin was added, and plates were incubated at 
room temperature for an additional 30 min. After a final wash, 
nitrophenyl phosphate substrate was added. The colorimetric 
reaction was terminated by adding 0.5 N sodium hydroxide per 
well and the optical densities of individual wells were deter-
mined at 405 nm using a standard microplate spectrophotom-
eter (Wallac Victor 2, Perkin Elmer, Waltham, MA, USA). 
Statistical analysis
Serum levels of S-EDP and anti-elastin antibody in SSc patients 
and healthy controls were compared using the Mann-Whitney 
U test. The levels of S-EDP and anti-elastin antibody in SSc pa-
tients and in healthy controls were analyzed using the Mann-
Whitney U test and analysis of covariance. Associations between 
continuous variables and S-EDP or anti-elastin antibody levels 
were analyzed using Spearman’s correlation analysis. All statis-
tical analyses were two-tailed and P values of  < 0.05 were con-
sidered significant. Statistical analysis was performed using 
SPSS version 12.0K.
Ethics statement
The study protocol was reviewed and approved by the institu-
tional review board of Seoul National University (IRB No. H-0912-
013-302). Informed consent was obtained from the patients 
and healthy controls.Hong YJ, et al.  •  S-EDP and Anti-Elastin Antibody in Systemic Sclerosis
486   http://jkms.org http://dx.doi.org/10.3346/jkms.2012.27.5.484
RESULTS
Of the 79 patients, 75 (95%) were females; 37 patients had the 
limited cutaneous subtype and 42 patients the diffuse cutane-
ous subtype. Mean age (± SD) at diagnosis was 49.7 ± 12.2 yr 
and disease duration (mean ± SD) was 9.3 ± 7.3 yr. Anti-centro-
mere antibody was found in 11 patients and anti-Scl-70 antibody 
in 51 patients. Modified Rodnan skin scores were available for 
47 (59.5%) patients. Eight patients had heart involvement, 5 had 
pulmonary arterial hypertension, and 59 had lung involvement. 
Only one patient had kidney involvement, and thus, kidney in-
volvement was not analyzed as a variable. 
  The serum concentrations of S-EDP in SSc patients (median 
[range], 144.44 ng/mL [80.06, 583.25]) were significantly higher 
than in healthy controls (median [range], 79.59 ng/mL [45.75, 
180.55]) as shown in Fig. 1 (P < 0.001, by Mann-Whitney U test). 
Age was positively correlated with S-EDP level in SSc patients 
(Spearman’s ρ = 0.245, P = 0.029), but negatively correlated in 
controls (Spearman’s ρ = -0.322, P = 0.003, by Spearman’s cor-
relation analysis). In addition, S-EDP levels were found to be 
correlated with disease duration in SSc (Spearman’s ρ = 0.346, 
P = 0.002, by Spearman’s correlation analysis), and especially, 
in the diffuse cutaneous subtype (diffuse: Spearman’s ρ = 0.429, 
P = 0.005; limited: Spearman’s ρ = 0.212, P = 0.214, by Spear-
man’s correlation analysis, Fig. 2). Serum levels of S-EDP were 
not different between patients with limited SSc and diffuse SSc 
(P = 0.829, by Mann-Whitney U test) (Table 1). Furthermore, S-
EDP levels were not found to be associated with the presence  
of anti-centromere antibody (P = 0.892), anti-Scl70 antibody 
(P = 0.581), interstitial lung disease (P = 0.660), heart involve-
ment (P = 0.667), or pulmonary hypertension (P = 0.163, all P 
values by Mann-Whitney U test). The correlation between S-EDP 
levels and modified Rodnan skin scores was not significant in 
all patients, or in patients with the diffuse cutaneous or limited 
cutaneous subtypes (total, P = 0.280; diffuse, P = 0.176; limited, 
P = 0.990, by Spearman’s correlation analysis). After adjusting 
for disease duration, S-EDP levels were not found to be depen-
dent on the presence of clinical features, anti-Scl70 antibody or 
anti-centromere antibody.
  The serum concentrations of anti-elastin antibodies were ele-
vated in SSc patients versus controls (median [range], SSc: 0.222 
U [0.050, 3.548], controls: 0.191 U [0.004, 3.796], P = 0.049, by 
Mann-Whitney U test). Neither age nor disease duration was 
Table 1. Serum concentrations of soluble elastin-derived peptides (S-EDP) in sys-
temic sclerosis patients according to clinical characteristics
Chracteristics No.  S-EDP (ng/mL) P value*
Skin involvement
   Limited
   Diffuse
 
37
42
  
165.49 (80.06, 326.78)
139.99 (94.03, 315.78)
  
0.829
ILD
   Positive
   Negative
 
59
20
 
152.21 (85.76, 326.78)
140.77 (90.06, 316.07)
 
0.660
Heart involvement
   Positive
   Negative
 
  6
69
 
198.83 (95.92, 235.01)
155.21 (80.06, 583.25)
 
0.667
PAH
   Positive
   Negative
 
  5
46
 
95.92 (80.06, 225.06)
155.21 (80.06, 326.78)
 
0.163
Anti-centromere
   Positive
   Negative
 
11
67
 
175.78 (80.06, 210.88)
144.39 (85.76, 326.78)
 
0.892
Anti-Scl-70
   Positive
   Negative
 
51
27
 
152.21 (89.25, 315.81)
138.71 (80.06, 326.78)
 
0.581
Data are presented as medians (ranges). *by the Mann Whitney U test. ILD, interstitial 
lung disease; PAH, pulmonary arterial hypertension.
Fig. 1. Serum concentrations of S-EDP in SSc patients. Serum concentrations of S-
EDP in SSc patients were significantly higher than those in healthy controls (P < 0.001, 
by Mann-Whitney U test). The thick horizontal lines in boxes are medians and the up-
per and lower sides of the boxes represent upper and lower quartiles, respectively. The 
horizontal bars above and below each box represent highest and lowest values within 
the 1.5 times of interquartile range and circles represent outliers. 
S
-
E
D
P
 
(
n
g
/
m
L
)
  SSc  Control
600
500
400
300
200
100
0
Fig. 2. The levels of S-EDP and disease durations in systemic sclerosis. The levels of 
S-EDP and disease durations were correlated in systemic sclerosis (Spearman’s ρ = 
0.346, P = 0.002) and especially diffuse cutaneous subtype (Spearman’s ρ = 0.429, 
P = 0.005). 
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correlated with anti-elastin antibody in SSc patients (age, P =  
0.267; disease duration, P = 0.363, by Spearman’s correlation 
analysis). However, anti-elastin antibody levels were significant-
ly higher in the diffuse cutaneous subtype than in the limited 
cutaneous subtype (P = 0.031, by Mann-Whitney U test), and 
anti-elastin antibody levels were found to be higher in the ab-
sence of anti-centromere antibody (P = 0.023, by Mann-Whitney 
U test), but anti-elastin antibody levels was not found to be cor-
related with modified Rodnan skin scores or any other clinical 
organ involvements (Table 2). S-EDP and anti-elastin antibody 
levels were not correlated in SSc patients (P = 0.628), and in the 
diffuse (P = 0.575) and limited cutaneous subtypes (P = 0.929). 
 
DISCUSSION
This study showed that serum levels of S-EDP and anti-elastin 
antibody were elevated in SSc patients versus healthy age- and 
sex-matched control. Moreover, a positive association was found 
between S-EDP levels and disease duration, which supports the 
suggestion that EDP is closely related to disease process. Fur-
thermore, anti-elastin antibody level was found to be increased 
in diffuse cutaneous SSc and in the absence of anti-centromere 
antibody.
  The reason why the level of S-EDP increased in SSc is not clear. 
The correlations between S-EDP levels and disease duration or 
age might provide clues to the reason for this phenomenon. In 
previous morphologic studies, the aging process was found to 
cause increase in elastic fiber (16) and elastic fiber had changes 
suggestive of degradation in the normal skin age-dependently 
(8). However, in this study, age was found to be inversely corre-
lated with S-EDP levels, in healthy controls. This discrepancy 
could be attributed to the limitation in morphologic study. Thus, 
the increased S-EDP level found in SSc cannot be attributed to 
the aging process, but rather to disease duration, which means 
that S-EDP is probably associated with the pathologic process. 
Previously, in a small-scale study, disease duration was not found 
to be associated with elastin in the skin (9), but in a morphologic 
analysis, elastic fiber was found to be increased in SSc skin as 
compared with normal skin (8). Abundant elastin in the skin 
can be abnormal (17) and actively degraded by adjacent cells 
(18), which may be the cause of an increase in serum S-EDP in 
SSc patients. In a previous study, it was found that desmosine 
and isodesmosine, cross-link amino acids from elastin, increased 
in the urine of SSc patients, which supports our results (10). 
  Elastin is known to be present in blood vessels and lung tis-
sues, which can also be sources of EDP, which is produced by 
several enzymes, including elastase from leukocytes. Further-
more, several authors have suggested that active inflammation 
in SSc can augment the degradation of elastin. Desmosine and 
isodesmosine released during elastin degradation have been 
reported to be negatively associated with the carbon monoxide 
diffusion capacity of the lung in SSc (10) and interstitial lung dis-
ease in SSc has been associated with the levels of serum or bron-
choalveolar lavage fluid neutrophil elastase (19, 20). Pulmonary 
hypertension has also been associated with elastin production 
and degradation (21, 22). In the present study, S-EDP levels were 
not found to be related to clinical subtypes, modified Rodnan 
skin scores, or organ involvement despite a relatively large co-
hort size and the enrollment of age-sex matched controls. It may 
be that the systemic nature of SSc and the time between elastin 
synthesis and degradation obscure differences in clinical sub-
types or organ involvement (including skin thickness). 
  EDP is known to have many different biologic effects, for ex-
ample, it can recruit fibroblasts, endothelial cells, and monocytes 
like chemokines (23-25), and also stimulates arterial smooth 
muscle cell proliferation (26) and Th1 differentiation (27). The 
precise role played by EDP in SSc is not known, but in view of 
the effect that EDP has on different cells, it appears to be a can-
didate for involvement in the pathogenesis in SSc. Further func-
tional studies on EDP are required to explore its role in SSc.
  Previously, the presence of anti-elastin antibody was consid-
ered to reflect elastin degradation (28). However, in the present 
study, levels of EDP, the direct product of elastin degradation, 
were not found to be correlated with anti-elastin antibody levels. 
Serum anti-elastin antibody levels are known to increase in var-
ious connective tissue diseases (12) and humoral and cell-me-
diated immune response against elastin in SSc patients has been 
demonstrated (11), which suggests that anti-elastin antibody 
production is as a result of a secondary response to increased 
elastin production or degradation. The association of anti-elas-
tin antibody with diffuse cutaneous subtype or negativity of an-
ti-centromere antibody may reflect different immunologic pro-
Table 2. Serum anti-elastin antibodies levels in systemic sclerosis patients according 
to clinical characteristics
Characteristics  No. Anti-elastin antibodies (U) P value*
Skin involvement
   Limited
   Diffuse
  
36
41
  
0.204 (0.050, 2.063)
0.368 (0.060, 3.548)
  
0.031
ILD
   Positive
   Negative
  
58
19
  
0.231 (0.060, 2.821)
0.222 (0.050, 3.548)
  
0.962
Heart involvement
   Positive
   Negative
  
  6
66
  
0.378 (0.222, 0.956)
0.217 (0.050, 3.548)
  
0.081
PAH
   Positive
   Negative
  
  4
46
  
0.324 (0.217, 0.701)
0.262 (0.050, 3.548)
  
0.520
Anti-centromere
   Positive
   Negative
 
11
65
 
0.126 (0.060, 0.701)
0.254 (0.050, 3.548)
 
0.023
Anti-Scl-70
   Positive
   Negative
 
50
26
 
0.217 (0.060, 3.548)
0.260 (0.050, 2.889)
 
0.810
Data are presented as medians (ranges). *by Mann-Whitney U test. ILD, interstitial lung 
disease; PAH, pulmonary arterial hypertension.Hong YJ, et al.  •  S-EDP and Anti-Elastin Antibody in Systemic Sclerosis
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files in each subtype.
  In summary, serum levels of S-EDP and anti-elastin antibody 
are elevated in SSc patients versus healthy age- and sex-matched 
control. The serum level of S-EDP was associated with disease 
duration. Moreover, anti-elastin antibody level was increased in 
diffuse cutaneous SSc and in the absence of anti-centromere 
antibody.  
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